Literature DB >> 22388584

New therapies for pneumonia.

Jean-Damien Ricard1.   

Abstract

PURPOSE OF REVIEW: Acute respiratory tract infections are a key public health problem, and represent a major cause of death worldwide. The dramatic shortage of new antibiotics combined with the increasing number of antibiotic-resistant bacteria constitutes a worrisome threat for the global population and a critical challenge for healthcare institutions. Over recent years, a better understanding of bacterial growth, metabolism, and virulence has offered several potential targets for nonantibiotic antimicrobial therapies. RECENT
FINDINGS: Several leads have been investigated, targeting adhesion, communication, toxins, virulence factors, direct bacterial killing by bacteriophages, and vaccine strategies. Promising results have been obtained with these different targets, including inhibition of quorum sensing, use of pilicide compounds to inhibit bacterial adhesion, prevention and treatment of Pseudomonas aeruginosa pneumonia by bacteriophages, effective protection against P. aeruginosa lung infection with mucosal vaccination, use of anti-PcrV antibodies in P. aeruginosa-induced sepsis.
SUMMARY: Expectations are high regarding the translation of these experimental results into true clinical benefits for the patients. Importantly, clinical studies are ongoing in some areas, and promising preliminary results have already been obtained in some instances.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22388584     DOI: 10.1097/MCP.0b013e3283520fec

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  4 in total

1.  Candida colonization in ventilated ICU patients: no longer a bystander!

Authors:  Jean-Damien Ricard; Damien Roux
Journal:  Intensive Care Med       Date:  2012-06-15       Impact factor: 17.440

2.  Pathophysiology of Escherichia coli ventilator-associated pneumonia: implication of highly virulent extraintestinal pathogenic strains.

Authors:  Jonathan Messika; Fatma Magdoud; Olivier Clermont; Dimitri Margetis; Stéphane Gaudry; Damien Roux; Catherine Branger; Didier Dreyfuss; Erick Denamur; Jean-Damien Ricard
Journal:  Intensive Care Med       Date:  2012-09-28       Impact factor: 17.440

3.  Interactions among quorum sensing inhibitors.

Authors:  Rajat Anand; Navneet Rai; Mukund Thattai
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

4.  Antibody Treatment against Angiopoietin-Like 4 Reduces Pulmonary Edema and Injury in Secondary Pneumococcal Pneumonia.

Authors:  Liang Li; Benjamin Jie Wei Foo; Ka Wai Kwok; Noriho Sakamoto; Hiroshi Mukae; Koichi Izumikawa; Stéphane Mandard; Jean-Pierre Quenot; Laurent Lagrost; Wooi Keong Teh; Gurjeet Singh Kohli; Pengcheng Zhu; Hyungwon Choi; Martin Lindsay Buist; Ju Ee Seet; Liang Yang; Fang He; Vincent Tak Kwong Chow; Nguan Soon Tan
Journal:  mBio       Date:  2019-06-04       Impact factor: 7.867

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.